BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)

BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE)

CONDITION

Neurological

GENDER

Both males and females

AGE GROUP

18 years and above

TRIAL STATUS

Active, not recruiting

A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects with Relapsing-Remitting Multiple Sclerosis.

The primary objective of this study is to evaluate the long-term safety profile of BG00012 (dimethyl fumarate).

Secondary objectives of this study are to evaluate the long-term efficacy of BG00012 using clinical endpoints and disability progression, to evaluate further the long-term effects of BG00012 on multiple sclerosis (MS) brain lesions on magnetic resonance imaging (MRI) scans in participants who had MRI scans as part of Studies 109MS301 (NCT00420212) and 109MS302 (NCT00451451) and to evaluate the long-term effects of BG00012 on health economics assessments and the visual function test.

CONTACT DETAILS

Phone Number: 
Email: 
Location: Suite 5, 12 Thomas Street, Chatswood, New South Wales, Australia

CONTACT SITE

Approved By: Northern Sydney Local Health District Research Office              

Clinical Trial Registry Link: